Twist Bioscience shares are trading higher after Guggenheim initiated coverage on the stock with a Buy rating and announced a price target of $53.
Portfolio Pulse from Benzinga Newsdesk
Twist Bioscience shares are trading higher after Guggenheim initiated coverage on the stock with a Buy rating and announced a price target of $53.
June 05, 2024 | 3:04 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Twist Bioscience shares are trading higher following Guggenheim's initiation of coverage with a Buy rating and a $53 price target.
The Buy rating and price target of $53 from Guggenheim is a positive signal for investors, likely driving the stock price higher in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100